Eyeing their first approval, BridgeBio sends their first drug to the FDA and lands a speedy review

Over the last five years, BridgeBio has raised about $1 billion, assembled over 20 different companies, extended networks into China and Israel and scored partnerships with a handful of top academic centers. Now, for the first time, they’ll have a drug before the FDA.